Why the study?
With TAVI indications expanding to younger, lower-risk patients, long-term transcatheter aortic valve durability has become an emerging issue requiring review of evidence under standardized definitions.
What is the current evidence regarding transcatheter aortic valve durability, types of failure, and strategies for treatment such as re-do TAVI?
What is the current evidence regarding transcatheter aortic valve durability, types of failure, and strategies for treatment such as re-do TAVI?
Current evidence demonstrates very low rates of structural valve deterioration up to 8 years post-TAVI, supporting its expansion to younger patients and highlighting re-do TAVI as a viable treatment for valve failure.
No takes yet. Share an insight, caveat, or question.
May support TAVI counseling in younger patients; leaves open prospective durability and re-do trials.
Costa et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: